Anales de la RANM

249 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PROTONTERAPIA CLÍNICA 2030 Calvo Manuel FA, et al. An RANM. 2023;140(03): 233 - 251 • Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, ERAPERMED PerPlanRT, AC20/00123 and AC20/00102). Co-funded by the European Union, FEDER funds under the ERA PerMed ERA-NET Program. • Instituto Carlos III PI20/01598. • Horizon 2020 EU H2020-SU-DS-2018-2019-2020. • Ministry of Science, Innovation and Education PID 2019-104558RB-100. • Siemens International C00232756/PR20-00445. BIBLIOGRAFÍA 1. Mohan R. A review of proton therapy: Cu- rrent status and future directions. Precis Ra- diat Oncol. 2022; 6(2): 164-176. doi: 10.1002/ pro6.1149. 2. Cao W, Rocha H, Mohan R et al. Reflections on beam configuration optimization for intensi- ty-modulated proton therapy. Phys Med Biol. 2022; 67(13). DOI: 10.1088/1361-6560/ac6fac 3. Baumann BC, Mitra N, Harton JG et al. Compa- rative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for lo- cally advanced cancer. JAMA Oncol. 2020; 6(2): 237-246. doi: 10.1001/jamaoncol.2019.4889 4. Lassaletta Á, Morales JS, Valenzuela PL et al. Neurocognitive outcomes in pediatric brain tu- mors after treatment with proton versus photon radiation: a systematic review and meta-analy- sis. World J Pediatr. 2023; 19(8): 727-740. doi: 10.1007/s12519-023-00726-6 5. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016; 95(1): 267-78. doi: 10.1016/j.ijro- bp.2015.10.025 6. Indelicato DJ, Bates JE, Mailhot Vega RB et al. Second tumor risk in children treated with pro- ton therapy. Pediatr Blood Cancer. 2021; 68(7): e28941. DOI: 10.1002/pbc.28941 7. Lee A, Woods R, Mahfouz A et al. Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carci- noma. JAMA Netw Open. 2023; 6(1): e2250607. doi: 10.1001/jamanetworkopen.2022.50607 8. Allen AM, Pawlicki T, Dong L et al. An evidence based review of proton beam therapy: the re- port of ASTRO’s emerging technology commit- tee. Radiother Oncol. 2012; 103 (1): 8-11. doi: 10.1016/j.radonc.2012.02.001 9. Chabra AM, Rice SR, Holtzman A et al. Cli- nical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the proton collaborative group prospective re- gistry. Radiother Oncol. 2023; 183: 109551. doi: 10.1016/j.radonc.2023.109551 10. Hong S, Mahajan A, Laack NN et al. Compari- son of tumor control after stereotactic radiosur- gery or pencil beam proton therapy for newly diagnosed clival chordomas: a single-center re- trospective study. World Neurosurg. 2023; 178: e510-e519. doi: 10.1016/j.wneu.2023.07.109 11. Mattke M, Ohlinger M, Bougatf N et al. Proton and carbon ion beam treatment with active ras- ter scanning method in 147 patients with skull base chordoma at the Heidelberg Ion Beam The- rapy Center-a single-center experience. Stra- hlenther Onkol. 2023 Feb;199(2):160-168. doi: 10.1007/s00066-022-02002-4. Epub 2022 Sep 23. PMID: 36149438; PMCID: PMC9876873 12. Nie M, Chen L, Zhang J, Qiu X. Pure proton therapy for skull base chordomas and chondro- sarcomas: A systematic review of clinical expe- rience. Front Oncol. 2022 Nov 25;12:1016857. doi: 10.3389/fonc.2022.1016857. PMID: 36505855; PMCID: PMC9732011. 13. Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for pa- tients with hepatocellular carcinoma: a sys- tematic review and meta-analysis. Radiot Oncol. 2015; 114(3): 289-295. doi: 10.1016/j. radonc.2014.11.033 14. Bush DA, Volk M, Smith JC et al. Proton beam radiotherapy versus transarterial chemoembo- lization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer 2023; 129(22): 3554-3563 doi: 10.1002/cncr.34965 . Online ahead of print. 15. Chuong MD, Kaiser A, Khan F et al. Consen- sus report from the Miami Liver Proton Thera- py Conference. Front Oncol. 2019; 9: 457. doi: 10.3389/fonc.2019.00457 . 16. Gogineni E, Chen H, Istl AC, Johnston FM, Narang A, Deville C jr. Comparative in silico analysis of ultra-hypofractionated intensity- modulated photon radiotherapy (imrt) versus intensity-modulated proton therapy (impt) in the pre-operative treatment of retroperitoneal sarcoma. Cancers (Basel). 2023; 15(13): 3482. doi: 10.3390/cancers15133482 17. Manzar GS, Lester SC, Routman DM et al. Comparative analysis of acute toxicities and patient reported outcomes between Intensity- Modulated Proton Therapy (IMPT) and Volu- metric Modulated Arc Therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol. 2020; 147: 64-74. doi: 10.1016/j.ra- donc.2020.03.010 18. Lee A, Kitpanit S, Chilov M, Langendijk JA, Lu J, Lee NY. A systematic review of proton the- rapy for the management of nasopharyngeal cancer. Int J Part Ther. 2021; 8(1): 119-130. doi: 10.14338/IJPT-20-00082.1 19. Hasan S, Lazarev S, Garg M et al. Proton therapy for high-risk prostate cancer: Results from the Pro- ton Collaborative Group PCG 001-09 prospective registry trial. Prostate. 2023; 83(9): 850-856. 20. Kubeš J, Haas A, Vondráček V et al. Ultrahy- pofractionated proton radiation therapy in the treatment of low and intermediate-risk prosta- te Cancer-5-Year outcomes. Int J Radiat Oncol Biol Phys. 2021; 110: 1090-1097. doi: 10.1002/ pros.24525